Bibliographie : Cannabinoïdes et autismes / TED / psychoses infantiles. Dr Christian Sueur, GRECC, version actualisée avril 2020.
Lire la suiteBibliographie : Mescaline et Peyotl Dr Christian SUEUR, GRECC, avril 2020. 1 - Mescaline et Peyotl, Histoire et culture : 1 - 2 2 - Neuro-Psychophysiologie de la mescaline : 3 - 4 3 - Pharmacologie de la mescaline : 5 - 7 4 - Toxicologie de la mescaline : 8 5 - Complications psychiatriques de la mescaline : 8 6 - Ethnopharmacologie du Peyotl : 9 - 11 7 - Mescaline et thérapie psychédélique : 12 - 13
Lire la suiteA Review of Human Studies Assessing Cannabidiol’s (CBD) Therapeutic Actions and Potential C. Michael White The Journal of Clinical Pharmacology, 2019, 59, (7) 923–934 Doi : 10.1002/jcph.1387 Abstract Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. Numerous CBD products are available, ranging from a US Food and Drug Administration (FDA) approved product called Epidiolex to products created for medical marijuana dispensaries and products sold in smoke shops, convenience stores, and over the Internet.The legal status of the non–FDA approved products differs depending on the source of the CBD and the state,while the consistency and quality of the non–FDA-approved [...]
Lire la suiteCannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice Andreza B. Sonego; Felipe V. Gomes; Elaine A. Del Bel; Francisco S. Guimaraes Behavioural Brain Research, 2016, 21. Doi : 10.1016/j.bbr.2016.04.042 Highlights Cannabidiol (CBD) attenuated haloperidol-induced catalepsy. CBD reduced c-Fos protein expression in the dorsal striatum induced by haloperidol. CBD effects were blocked by 5-HT1A receptor antagonist. Abstract Cannabidiol (CBD) is a major non-psychoactive compound from Cannabis sativa plant. Given that CBD reduces psychotic symptoms without inducing extrapyramidal motor side-effects in animal models and schizophrenia patients, it has been proposed to act as an atypical antipsychotic. In addition, CBD [...]
Lire la suiteIs There a Role for Cannabis in Mental Health Disorders ? Pauline Anderson & Charles P. Vega, Medscape, CME / ABIM MOC / CE Released : 12/13/2019 https://www.medscape.org/viewarticle/922367 Clinical Context The most common indication for the use of medicinal cannabis is pain, although the results of studies of cannabis products for chronic pain are mixed. Häuser and colleagues performed a review of systematic reviews of cannabis for chronic pain conditions, and their results were published in the October 15, 2017 issue of European Journal of Pain.[1] Reviewers evaluated 10 systematic reviews of cannabis for pain. Methodological quality was high in 4 of the reviews. There was [...]
Lire la suiteAcceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia Jan van Amsterdam, Jojanneke Vervloet, Gerdien de Weert, Victor J. A. Buwalda, Anna E. Goudriaan and Wim van den Brink Harm Reduction Journal, 2018, 15, 47, 1-4. Doi : 10.1186/s12954-018-0253-7 Abstract Background : Cannabis-smoking patients with a psychotic disorder have poorer disease outcomes than non-cannabis-smoking patients with poorest outcomes in patients smoking high-potency cannabis (HPC) containing high Δ9-tetrahydrocannabinol (THC) and low cannabidiol (CBD). Quitting cannabis smoking or substitution of HPC by cannabis variants containing less THC and/or more CBD may benefit these patients. The present study explores whether daily HPC-smoking patients with schizophrenia accept smoking [...]
Lire la suiteAdolescent Cannabis Use : What is the Evidence for Functional Brain Alteration ? V. Lorenzetti, S. Alonso-Lanaa, G. J. Youssef, A. Verdejo-Garcia, C. Suo, J. Cousijn, M. Takagi, M. Yücel and N. Solowij Current Pharmaceutical Design, 2016, 22, 1-14. DOI: 10.2174/1381612822666160805155922 Abstract Background : Cannabis use typically commences during adolescence, a period during which the brain undergoes profound remodeling in areas that are high in cannabinoid receptors and that mediate cognitive control and emotion regulation. It is therefore important to determine the impact of adolescent cannabis use on brain function. Objective : We investigate the impact of adolescent cannabis use on brain function by reviewing the functional [...]
Lire la suitePsychiatry & the psychedelic drugs. Past, present & future James J.H. Rucker, Jonathan Iliff, David J. Nutt Neuropharmacology, 2018, 142, 200e218 https://doi.org/10.1016/j.neuropharm.2017.12.040 a b s t r a c t The classical psychedelic drugs, including psilocybin, lysergic acid diethylamide and mescaline, were used extensively in psychiatry before they were placed in Schedule I of the UN Convention on Drugs in 1967. Experimentation and clinical trials undertaken prior to legal sanction suggest that they are not helpful for those with established psychotic disorders and should be avoided in those liable to develop them. However, those with so-called ‘psychoneurotic’ disorders sometimes benefited considerably from their tendency to [...]
Lire la suiteGene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis Miquel Bioque, Sergi Mas, Maria Cristina Costanzo, Bibiana Cabrera, Antonio Lobo, Ana González-Pinto, Elisa Rodriguez-Toscano, Iluminada Corripio, Eduard Vieta, Immaculada Baeza, Ángela Ibáñez, Miguel Gutiérrez Fraile, Manuel J. Cuesta, Gisela Mezquida, Amalia Lafuente, Miguel Bernardo, PEPs GROUP European Neuropsychopharmacology, 2019, 29, (6), 786-794 https://doi.org/10.1016/j.euroneuro.2019.04.005 Abstract Alterations of the endocannabinoid system (ECS) may play an important role in the development of schizophrenia and other psychotic disorders. Cannabis use is one of the environmental fac- tors more repeatedly related to an increase the risk of developing a psychotic episode, while its [...]
Lire la suiteComment le cannabis peut favoriser les troubles psychotiques : conséquences, dépistage et prise en charge Alain Dervaux L’Information Psychiatrique, 2019, 95, (8), 672-678 * Travail présenté aux 37es journées de la Société de l’Information Psychiatrique, Antibes, 4-6 octobre 2018. Résumé Les relations complexes entre cannabis et psychoses ont fait l’objet de nombreux travaux depuis une vingtaine d’années. La consommation de cannabis peut s’accompagner de symptômes psychotiques chez certains sujets (jusqu’à 15 % des consommateurs) qui disparaissent avec l’élimination du -9-THC de l’organisme. Elle peut aussi augmenter par deux le risque de troubles psychotiques, notamment de schizophrénie. Le risque est d’autant plus élevé que la consommation de cannabis [...]
Lire la suite